* Madrigal Pharmaceuticals Inc MDGL.OQ reported a
quarterly
adjusted loss of $7.10 per share for the quarter ended in
June, lower than the same quarter last year, when the company
reported EPS of $-4.69. The mean expectation of
fifteen analysts for the quarter was for a loss of $7.53 per
share. Wall Street expected results to range from $-9.37
to $-6.52 per share.
* Revenue was $14.64 million; analysts expected $3.90
million.
* Madrigal Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of $7.10.
* The company reported a quarterly loss of $151.97 million.
* Madrigal Pharmaceuticals Inc shares had fallen by 4.9%
this
quarter and gained 15.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 0.7%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Madrigal
Pharmaceuticals Inc is $385.00
This summary was machine generated from LSEG data August 7 at
01:52 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -7.53 -7.10 Beat
Mar. 31 2024 -6.28 -7.38 Missed
Dec. 31 2023 -5.28 -5.68 Missed
Sep. 30 2023 -4.93 -5.34 Missed